With expectations to work after hours and a growing administrative burden, some say “radical” action is needed.

More than half of US adults are eligible for primary prevention with statins, yet lipid-lowering therapies remain underused.

In addition to giving patients standard verbal breath-holding instructions, the segment offers them an idea of what to expect ...

Recommendations around dosing, duration, and patient-specific options are woven into the fabric of the scientific statement.

Results from the DAPT-MVD trial, while not necessarily generalizable, do open the door to a new tactic in select cases.

The pilot study provides “a good illustration of how AI can be an augmentation to our current processes,” Thomas Maddox says.

The US Food and Drug Administration has approved enlicitide (Lipfendra) as the first oral PCSK9 inhibitor for reducing LDL ...

Michael Mack and Vinay Badhwar join Roxana Mehran to discuss how changes in coverage could impact patients and heart teams.

Without changes, including initiatives that help everyone at risk, past progress in slowing IHD’s damage may be further ...

Differences in various efficiency metrics were modest, but “minutes matter in stroke,” Shyam Prabhakaran says.

More than one in 10 patients with no coronary calcium had noncalcified plaque, putting them at greater risk for MACE.

A new statement makes the case for identifying recruits at risk of sudden cardiac death and older personnel at risk of CVD.